Page 75 - Read Online

Page 8 of 12 Yonemura et al. J Cancer Metastasis Treat 2022;8:43 https://dx.doi.org/10.20517/2394-4722.2022.49

Table 2. Results of no CRS and systemic chemotherapy [24] , radiation and palliative surgery [25] , and CRS + POC [26-32]
Median 5-, 10-year Favorable
Authors + Eligibility, No of Complications 1-year
A22:I22 Study type treatments cases survival after CRS survival survival rate prognostic
factors
(-year)
(months)
Kaya et al. [26] Retrospective No CRS and SC 35 16.2 (2-52) 55 0% Age ≤ 60 years
study old
2005-2013 P Asbestos
exposure ≤ 20
years
ECOG PS = 0-2
[27]
Salo et al. Retrospective Radiation/palliative 46 1 to 2 100% 0%-14% Not described
study surgery
2000-2012
Sugarbaker Retrospective Potentially curable 68 66 Grade 3,4:23.5% 83% 5- years: 50% PCI ≤ 28, CCR-
[28]
et al. + study 0-2,
A26:J38
1989-2003 CRS + POC Grade 5: 7% 10- years:35% No metastasis
[29]
Baratti et al. Retrospective ECOG PS ≤ 2, age ≤ 108 63.2 Grade 3-5 38.9% 85% 5- years: 52.4% Epithelial type,
study 75 MIB1 index ≤ 10
1996-2012 Potentially curable Grade 5: 1.9% 10- No LN meta.
years:44.6%
No extraperitoneal
disease
CRS + POC (NAC,
HIPEC)
Kepenekian Retrospective Age ≤ 80, ECOG PS 126 61 Grade 3,4: 39% 60% 5- years: 28% PCI ≤ 30, CC-
[30]
et al. analysis ≤ 1 0,1,
1991-2014 CRS + NAC + HIPEC Grade 5: 3% 10- years: 14% Absence of NAC
Alexander Retrospective Potentially curable 211 38.4 Grade3,4: 30% 5- years: 41% Age < 60,
[31]
et al. analysis histologic grade:
low
0 1992-2011 CRS + HIPEC Grade 5: 2.3% 10- years: 26% CCR0,1, HIPEC:
CDDP vs. MMC
[32]
Helm et al. Review and Mean PCI: 12-29 1047 29-92 Morbidity: 8%- 70%- 17%-49% No relation with
meta-analysis 90% 87% EPIC, PCI 19
CRS + HIPEC Mortality: 0%-
8%
Kusamura PSOGI Potential curable 713 45 77.50% 5- years: Epitheloid, PCI-<
et al. [10] registration (PCI:14-29) 44.6% 12, CC-0,1
1981-2017 CRS + HIPEC Postoperative
complication:
grade 0-2
Our Retrospective Operable (PCI: 0- 68 23.4 Morbidity: 14.7% 57% 5- years: 29% Female, PCI ≤ 26
experiences analysis 39)
Yonemura CRS plus or minus Mortality: 2.9% 10- years: 12%
et al. [33]
POC
Magge Retrospective Potentially curable 65 46.20% 77% 5-years: 395 Age < 60, PCI <
[34]
et al. study 15, CC-0,1,
epitheloid
2001-2010 CRS + HIPEC
CRS: Cytoreductive surgery; POC: perioperative chemotherapy; HIPEC: hyperthermic intraperitoneal chemoperfusion; UI: under investigation; SC:
systemic chemotherapy.

[30]
factors . Naffouje et al. also reported that SC provided a short-term survival improvement at one year
alone, without adding any survival benefit beyond this time point . In contrast, Deraco et al. also studied
[36]
the role of perioperative SC using pemetrexed and CDDP in 116 DMPM patients with an ECOG
performance status of 0 and PCI < 20 . The patients were treated with CRS and HIPEC. They reported that
[37]
there was no significant difference in terms of survival between groups with preoperative chemotherapy,